thepharmaletter.com
Agomab reports positive interim data in Crohn's disease trial - The Pharma Letter
This is an early positive interim report of a new oral drug (ALK5 inhibitor) aimed at fibrostenosing Crohn’s disease. Treatments that target intestinal strictures are an important area of research for people with stricturing disease.
Patients with fibrostenosing (stricturing) Crohn’s disease, clinicians treating strictures, and researchers focused on anti‑fibrotic therapies and drug development.
What To Know
Why it matters Agomab has reported positive interim Phase IIa results for AGMB-129, an oral gut‑restricted ALK5 inhibitor being tested for fibrostenosing Crohn’s disease. The analysis covered 44 patients who completed 12 weeks and—according to the report—met the trial’s primary and secondary endpoints.
What to know The news is an early clinical update: AGMB‑129 is an investigational small molecule aimed at fibrostenotic disease (intestinal strictures).
The company says the study met safety/tolerability and secondary measures including pharmacokinetics and target engagement in strictures, based on an interim analysis of patients who finished 12 weeks of treatment.
AGMB‑129 is still in Phase IIa, so this is preliminary efficacy/safety information reported by the company rather than final results published in a peer‑reviewed journal. Details such as exact outcome measures, magnitude of effects, longer follow‑up, and independent review are not provided in the article text available here.
Next steps likely include completing the study, longer follow‑up, and more detailed data releases or presentations/publication. If you follow advances in anti‑fibrotic treatments for Crohn’s strictures, watch for full datasets and independent evaluation.
The article reports company‑released interim Phase IIa data (44 patients, 12 weeks) and is not a full peer‑reviewed publication. Interim results can change with larger numbers and longer follow‑up; the report focuses on safety/tolerability, PK, and target engagement rather than definitive clinical outcomes.
